Lexicon Pharmaceuticals, Inc.
LXRX Real Time Price USDRecent trades of LXRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in LXRX holdings by institutional investors
Quarterly net insider trading by LXRX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Apr 17, 2020 Issue: Pharmacy
LXRX Estimated quarterly lobbying spending
LXRX Revenue by Segment or Geography
New LXRX patent grants
-
Patent Title: Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use Jan. 09, 2018
-
Patent Title: Inhibitors of sodium glucose cotransporter 1 Jun. 27, 2017
-
Patent Title: Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use Jun. 20, 2017
-
Patent Title: 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use Apr. 18, 2017
-
Patent Title: Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use Aug. 02, 2016
-
Patent Title: Sodium glucose co-transporter inhibitors and methods of their use Jun. 14, 2016
-
Patent Title: Inhibitors of sodium glucose cotransporter 1 Dec. 01, 2015
-
Patent Title: Methods of treating diabetes Jun. 30, 2015
-
Patent Title: Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use Mar. 03, 2015
-
Patent Title: Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use Feb. 03, 2015
-
Patent Title: Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid Jul. 08, 2014
-
Patent Title: 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use Jul. 08, 2014
-
Patent Title: Multicyclic compounds and methods of their use Jul. 08, 2014
-
Patent Title: Monoclonal antibodies against angptl3 Jun. 03, 2014
-
Patent Title: Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate May. 27, 2014
-
Patent Title: (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone dihydrate and methods of its use Feb. 25, 2014
-
Patent Title: Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Feb. 18, 2014
-
Patent Title: Tryptophan hydroxylase inhibitors Jan. 14, 2014
-
Patent Title: Monoclonal antibodies against angptl4 Nov. 26, 2013
-
Patent Title: Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Nov. 05, 2013
-
Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as lim kinase 2 inhibitors Aug. 13, 2013
-
Patent Title: Sulfanyl-tetrahydropyran-based compounds and methods of their use Jul. 02, 2013
-
Patent Title: Compounds useful in the preparation of tryptophan hydroxylase inhibitors May. 28, 2013
-
Patent Title: Limk2 inhibitors, compositions comprising them, and methods of their use May. 28, 2013
-
Patent Title: Mst1 kinase inhibitors and methods of their use May. 14, 2013
-
Patent Title: Methods of treating pulmonary hypertension Apr. 02, 2013
-
Patent Title: Methods of treating ulcerative colitis Mar. 26, 2013
-
Patent Title: Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors Oct. 23, 2012
-
Patent Title: Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use Jul. 10, 2012
-
Patent Title: Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1- (4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Jun. 05, 2012
-
Patent Title: Limk2 inhibitors, compositions comprising them, and methods of their use Jun. 05, 2012
-
Patent Title: Aryl pyridines and methods of their use Apr. 10, 2012
-
Patent Title: Methods of using and compositions comprising tryptophan hydroxylase inhibitors Jan. 10, 2012
-
Patent Title: Methods of preparing imidazole-based compounds Jan. 10, 2012
-
Patent Title: Methods of treating rheumatoid arthritis Jan. 10, 2012
-
Patent Title: O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer Jan. 10, 2012
-
Patent Title: 4-amino-1h-pyrimidin-2-one based compounds, compositions comprising them and methods of their use Jan. 10, 2012
-
Patent Title: Monoclonal antibodies against angptl4 Jan. 10, 2012
-
Patent Title: Multicyclic amino acid derivatives and methods of their use Nov. 22, 2011
-
Patent Title: Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors Sep. 27, 2011
-
Patent Title: Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use Aug. 16, 2011
-
Patent Title: 1-phenyl-1h-pyrazole-based compounds Jun. 28, 2011
-
Patent Title: Methods of preparing imidazole-based bicyclic compounds Jun. 28, 2011
-
Patent Title: Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Jun. 28, 2011
-
Patent Title: Process for preparing 5-alkyl-7h-pyrrolo[2,3-d] pyrimindine-2-ols May. 31, 2011
-
Patent Title: Monoclonal antibodies against angptl3 May. 03, 2011
-
Patent Title: Synthesis of piperazines, piperidines and related compounds Apr. 05, 2011
-
Patent Title: Process for the preparation of substituted phenylalanines Mar. 01, 2011
-
Patent Title: Methods and compositions for treating pulmonary hypertension and related diseases and disorders Jan. 25, 2011
-
Patent Title: Process for the preparation of substituted phenylalanines Dec. 21, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to LXRX from public contracts
Recent insights relating to LXRX
Recent picks made for LXRX stock on CNBC
ETFs with the largest estimated holdings in LXRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $LXRX stock a Buy, Sell, or Hold?
- What is the price target for $LXRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $LXRX stock?
- Who owns the most shares of $LXRX stock?
- What funds own $LXRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view LXRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
- Address The Woodlands, TX
- Market Cap 530.6 million
- Employees 103
- Industrial Classification Pharmaceutical Preparations